Periprocedural Management of Chronically Anticoagulated Patients: A Practical Approach to Use of Novel Anticoagulants in Orthopedic Surgery

Fade E. Shamoun, Rayya A. Saadiq, Kyle S. Money, Adam J. Schwartz

Research output: Contribution to journalReview article

Abstract

Chronic anticoagulation is common in patients undergoing total joint arthroplasty (TJA). The newer novel oral anticoagulants dabigatran, rivaroxaban, and apixaban target individual factors in the clotting cascade (factors Xa, IIa). The stable pharmacokinetics of these medications provide improved efficacy and safety with equivalent or superior antithrombotic properties. There are no management guidelines for these newer anticoagulants in TJA. Understanding the pharmacokinetics, conventional laboratory tests, dosing, and reversal methods that can be used for coagulation hemostasis is crucial for surgeons who are deciding whether to operate now or later.

Original languageEnglish (US)
Pages (from-to)E161-E166
JournalAmerican journal of orthopedics (Belle Mead, N.J.)
Volume45
Issue number4
StatePublished - May 1 2016

Fingerprint

Arthroplasty
Anticoagulants
Orthopedics
Pharmacokinetics
Joints
Factor Xa
Blood Coagulation Factors
Hemostasis
Guidelines
Safety
Dabigatran
Surgeons
apixaban
Factor IIa
Rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Periprocedural Management of Chronically Anticoagulated Patients : A Practical Approach to Use of Novel Anticoagulants in Orthopedic Surgery. / Shamoun, Fade E.; Saadiq, Rayya A.; Money, Kyle S.; Schwartz, Adam J.

In: American journal of orthopedics (Belle Mead, N.J.), Vol. 45, No. 4, 01.05.2016, p. E161-E166.

Research output: Contribution to journalReview article

@article{3e077ac081be47928c96d1c54a984f36,
title = "Periprocedural Management of Chronically Anticoagulated Patients: A Practical Approach to Use of Novel Anticoagulants in Orthopedic Surgery",
abstract = "Chronic anticoagulation is common in patients undergoing total joint arthroplasty (TJA). The newer novel oral anticoagulants dabigatran, rivaroxaban, and apixaban target individual factors in the clotting cascade (factors Xa, IIa). The stable pharmacokinetics of these medications provide improved efficacy and safety with equivalent or superior antithrombotic properties. There are no management guidelines for these newer anticoagulants in TJA. Understanding the pharmacokinetics, conventional laboratory tests, dosing, and reversal methods that can be used for coagulation hemostasis is crucial for surgeons who are deciding whether to operate now or later.",
author = "Shamoun, {Fade E.} and Saadiq, {Rayya A.} and Money, {Kyle S.} and Schwartz, {Adam J.}",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "45",
pages = "E161--E166",
journal = "American Journal of Orthopedics",
issn = "1078-4519",
publisher = "Quadrant Healthcom Inc.",
number = "4",

}

TY - JOUR

T1 - Periprocedural Management of Chronically Anticoagulated Patients

T2 - A Practical Approach to Use of Novel Anticoagulants in Orthopedic Surgery

AU - Shamoun, Fade E.

AU - Saadiq, Rayya A.

AU - Money, Kyle S.

AU - Schwartz, Adam J.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Chronic anticoagulation is common in patients undergoing total joint arthroplasty (TJA). The newer novel oral anticoagulants dabigatran, rivaroxaban, and apixaban target individual factors in the clotting cascade (factors Xa, IIa). The stable pharmacokinetics of these medications provide improved efficacy and safety with equivalent or superior antithrombotic properties. There are no management guidelines for these newer anticoagulants in TJA. Understanding the pharmacokinetics, conventional laboratory tests, dosing, and reversal methods that can be used for coagulation hemostasis is crucial for surgeons who are deciding whether to operate now or later.

AB - Chronic anticoagulation is common in patients undergoing total joint arthroplasty (TJA). The newer novel oral anticoagulants dabigatran, rivaroxaban, and apixaban target individual factors in the clotting cascade (factors Xa, IIa). The stable pharmacokinetics of these medications provide improved efficacy and safety with equivalent or superior antithrombotic properties. There are no management guidelines for these newer anticoagulants in TJA. Understanding the pharmacokinetics, conventional laboratory tests, dosing, and reversal methods that can be used for coagulation hemostasis is crucial for surgeons who are deciding whether to operate now or later.

UR - http://www.scopus.com/inward/record.url?scp=85021852415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021852415&partnerID=8YFLogxK

M3 - Review article

C2 - 27327920

AN - SCOPUS:85021852415

VL - 45

SP - E161-E166

JO - American Journal of Orthopedics

JF - American Journal of Orthopedics

SN - 1078-4519

IS - 4

ER -